Non-Small Cell Lung Cancer with Chest Wall Involvement: Integrated Treatment or Surgery Alone?

Abstract

Background The aim of this study was to identify prognostic factors in patients affected by non-small cell lung cancer (NSCLC) with chest wall (CW) involvement, analyzing different strategies of treatment and surgical approaches.

Methods Records of 59 patients affected by NSCLC with CW involvement underwent surgery were retrospectively reviewed, from January 2000 to March 2013.

Results Induction therapy was administered to 18 (30.5%) patients while adjuvant treatment to 36 (61.0%). In 36 (61%) patients, lung resection was associated only with a parietal pleural resection while in 23 (39%) with CW en-bloc resection. Overall 5-year survival was 34%. Prognostic factors were evaluated in the 51 (86.4%) completely resected (R0) patients.

Five-year survival was 60% in patients undergoing induction therapy followed by surgery and 24% in those who underwent surgery as first treatment (p = 0.11). Five-year survival was better in the neoadjuvant group than that in the surgery group in IIB (T3N0) p-stage (100 vs 28%, p = 0.03), while in the IIIA (T3N1–2,T4N0) p-stage it was of 25 vs 0%, respectively (p = 0.53).

No 5-year survival difference was found in case of parietal pleural resection versus CW en-bloc resection (p = 0.27) and in case of only parietal pleural involvement versus soft tissue (p = 0.78).

In case of incomplete resection (R1), patients undergoing adjuvant radiotherapy had better 2-year survival than patients untreated: 60% vs 0% (p = 0.025).

Conclusions Type of surgical resection and the deep of infiltration of disease do not influence survival in this subset of patients. Integrated treatments seem to be suitable: neoadjuvant therapies ensure a better survival rate than surgery alone in IIB and IIIA patients, instead adjuvant radiotherapy proves a fundamental option in incomplete resections.

Keywords

lung cancer surgery - chest wall - surgery/incisions/exposure/techniques - neoadjuvant induction therapy - radiation therapy

• References

• 1 Grillo HC, Greenberg JJ, Wilkins Jr EW. Resection of bronchogenic carcinoma involving thoracic wall. J Thorac Cardiovasc Surg 1966; 51 (03) 417-421
• 2 Karmy-Jones R, Vallieres E. Non-small cell lung cancer with chest wall involvement. Chest 2003; 123 (05) 1323-1325
• 3 Downey RJ, Martini N, Rusch VW, Bains MS, Korst RJ, Ginsberg RJ. Extent of chest wall invasion and survival in patients with lung cancer. Ann Thorac Surg 1999; 68 (01) 188-193
• 4 Facciolo F, Cardillo G, Lopergolo M, Pallone G, Sera F, Martelli M. Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection. J Thorac Cardiovasc Surg 2001; 121 (04) 649-656
• 5 Gould PM, Bonner JA, Sawyer TE, Deschamps C, Lange CM, Li H. Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 45 (01) 91-95
• 6 Magdeleinat P, Alifano M, Benbrahem C. , et al. Surgical treatment of lung cancer invading the chest wall: results and prognostic factors. Ann Thorac Surg 2001; 71 (04) 1094-1099
• 7 Pairolero PC. Extended resections for lung cancer. How far is too far?. Eur J Cardiothorac Surg 1999; 16 (Suppl. 01) S48-S50
• 8 Lardinois D, De Leyn P, Van Schil P. , et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006; 30 (05) 787-792
• 9 www.nccn.org/professionals/physician_gls/pdf/nscl
• 10 Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481
• 11 Albertucci M, DeMeester TR, Rothberg M, Hagen JA, Santoscoy R, Smyrk TC. Surgery and the management of peripheral lung tumors adherent to the parietal pleura. J Thorac Cardiovasc Surg 1992; 103 (01) 8-12 , discussion 12–13
• 12 Trastek VF, Pairolero PC, Piehler JM. , et al. En bloc (non-chest wall) resection for bronchogenic carcinoma with parietal fixation. Factors affecting survival. J Thorac Cardiovasc Surg 1984; 87 (03) 352-358
• 13 Voltolini L, Rapicetta C, Luzzi L. , et al. Lung cancer with chest wall involvement: predictive factors of long-term survival after surgical resection. Lung Cancer 2006; 52 (03) 359-364
• 14 Doddoli C, D'Journo B, Le Pimpec-Barthes F. , et al. Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg 2005; 80 (06) 2032-2040
• 15 Ramnath N, Dilling TJ, Harris LJ. , et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e314S-e340S
• 16 Goldstraw P, Crowley J, Chansky K. , et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2 (08) 706-714
• 17 Douillard JY, Rosell R, De Lena M. , et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7 (09) 719-727
• 18 Suzuki M, Yoshida S, Moriya Y. , et al. Surgical outcomes of newly categorized peripheral T3 non-small cell lung cancers: comparisons between chest wall invasion and large tumors (>7 cm). Interact Cardiovasc Thorac Surg 2010; 11 (04) 420-424
• 19 Lee CY, Byun CS, Lee JG. , et al. The prognostic factors of resected non-small cell lung cancer with chest wall invasion. World J Surg Oncol 2012; 10: 9
• 20 De Pas T, Raimondi S, Pelosi G. , et al. A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. Acta Oncol 2010; 49 (04) 480-484